drugset / Trial / NCT06738303
Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to find out what treatment works best for participants with metastatic prostate cancer that are not responding to hormone treatment and docetaxel and are also Prostate-specific membrane antigen(PSMA) positive.
Timeline
- Start
- 2025-07-14
- Primary completion
- 2028-02-20
- Completion
- 2029-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cabazitaxel | Other / unclassified | 20 mg/m2 | Intravenous |
| Subject | Carboplatin | Small molecule | 4 unknown | Intravenous |
| Subject | Lu-PSMA-617 | Unknown | 7400 mbq | Intravenous |